Cellular DNA is under constant attack by a wide variety of agents, both endogenous and exogenous. To counteract DNA damage, human cells have a large collection of DNA repair factors. Among them, DNA polymerase lambda (Polλ) stands out for its versatility, as it participates in different DNA repair and damage tolerance pathways in which gap-filling DNA synthesis is required. In this work we show that human Polλ is conjugated with Small Ubiquitin-like MOdifier (SUMO) proteins both in vitro and in vivo, with Lys27 being the main target of this covalent modification. Polλ SUMOylation takes place in the nuclear pore complex and is mediated by the E3 ligase RanBP2. This post-translational modification promotes Polλ entry into the nucleus, which is required for its recruitment to DNA lesions and stimulated by DNA damage induction. Our work represents an advance in the knowledge of molecular pathways that regulate cellular localization of human Polλ, which are essential to be able to perform its functions during repair of nuclear DNA, and that might constitute an important point for the modulation of its activity in human cells.
INTRODUCTION
Cellular metabolism daily produces thousands of molecules that are able to generate a variety of DNA lesions, ranging from simple nucleotide changes to DNA breaks [1] . To deal with all DNA lesions, human cells have evolved a variety of repair mechanisms that ensure the maintenance of genome integrity at every cell cycle, avoiding the pathological consequences that might result from a defective response to DNA damage [2, 3] . Shortpatch DNA synthesis to fill small gaps is required in virtually all these DNA repair pathways. This gap-filling DNA synthesis is a singular reaction mainly performed by Xfamily specialized DNA polymerases [4] , which develop their abilities in diverse escenarios, such as base excision repair [5] , the repair of or tolerance to oxidative damage [6, 7] and the repair of DNA double strand breaks (DSBs) [8] [9] [10] [11] . Among the four PolX members identified in human cells to date, namely Polß, terminal deoxynucleotidyl transferase (TdT), Polµ, and Polλ, the latter shows the broadest range of action in DNA repair and tolerance to DNA damage [12] . Functional versatility of Polλ suggests interaction with multiple co-factors in the different pathways in which its gap-filling activity is required, probably implying a complex regulation. In agreement to this, previous studies have revealed cell cycle and DNA damage-dependent phosphorylation-mediated regulation of human Polλ [13] [14] [15] .
Post-translational modification (PTM) of proteins plays an essential role in the proper functioning and viability of eukaryotic cells. Amongst the different PTMs identified to date, conjugation of Small Ubiquitin-like MOdifier (SUMO) proteins seems crucial in human cells, as it plays relevant roles in key cellular processes, such as DNA replication, transcription and general maintenance of genomic stability [16] [17] [18] [19] . SUMOylation is a highly dynamic and transient process that promotes covalent attachment of SUMO moieties to specific lysine residues on target proteins. This reaction is reversible thanks to the existence of a variety of SUMO-specific proteases (SENPs) that efficiently remove SUMO proteins from targeted substrates [16, 17] . Importantly, SUMOylation can protect proteins from ubiquitin-mediated proteasomal degradation, probably competing with ubiquitination machinery for the same target lysine residues [17, 20] . In human cells, there are at least three main SUMO paralogs. SUMO1 shares approximately 45% sequence identity with SUMO2 and 3, and these two are 96% identical to each other. These SUMO proteins are approximately 12 kDa in size and structurally very similar to ubiquitin [20] . SUMO substrates are mainly proteins with nuclear functions, that can be modified either with a single SUMO moiety (mono-SUMO), multiple SUMO units at different sites (multi-3 SUMO) or with SUMO chains formed at one specific target site (poly-SUMO). In this regard, SUMO paralogs also differ in their ability to form polymeric chains, as SUMO2 and 3 possess internal Lys residues that can serve as SUMO acceptor sites in an automodification process that SUMO1 does not have [21] . Likewise, there are substantial differences in the dynamics of SUMO paralogs, because while SUMO1 is mainly found within the nucleoli, the nuclear envelope and cytoplasmic foci, SUMO2/3 are distributed throughout the nucleoplasm [22] . Moreover, whereas SUMO1 mainly exists in the proteinconjugated form, vertebrate cells have a large pool of free SUMO2/3 [22, 23] , which is conjugated to high molecular mass proteins when cells are subjected to protein-damaging stimuli [23, 24] . Covalent attachment of SUMO moiety to target proteins occurs in a threestep sequential process, frequently at specific consensus sequences [16, 17] . The SUMO conjugation process is initiated by covalent binding of SUMO protein to the SUMOactivating enzyme SAE1 (E1) through a thioester bond. This is followed by SUMO transference to a second factor, Ubc9 (E2), to form an E2-SUMO1 complex. Although Ubc9 can directly transfer the SUMO to acceptor Lys residues on target protein, this reaction is facilitated in vivo by a group of E3 protein ligases, whose mediation is specially relevant for substrate selection in proteins lacking SUMO acceptor consensus sequences [20] . The different SUMO E3 ligases identified so far have distinct subcellular localization, reflecting different biological functions of SUMO modification [25] . Accordingly, whereas RanBP2 is associated with the nuclear pore complex, and has been related to nucleocytoplasmic trafficking of specific proteins [26] , PIAS, Pc2/CBX4 and others are essentially found in the nucleus, where they play roles in a wide variety of biological processes, from transcription regulation and chromatin remodeling to the maintenance of cellular homeostasis and genome integrity [16, 17, 20] .
Here we report that DNA polymerase lambda (Polλ) is one of the protein targets for SUMOylation in human cells and uncover the biological role of this post-translational modification. We identify human Polλ lysine 27 (K27) as the main acceptor site for the covalent attachment of SUMO proteins both in vitro and in vivo, and demonstrate that the lack of SUMOylation results in deficient import of Polλ into the nucleus. We also identify the role of nuclear pore complex-associated RanBP2 protein as the main E3 ligase required for Polλ SUMOylation in the cytoplasm, allowing its entry into the nucleus and its function during DNA repair. Overall, our work provides insights into the regulation of Polλ during the DNA damage response and its potential use to control the quantity and/or quality of Polλ-mediated DNA repair events.
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RESULTS and DISCUSSION
Human Polλ is SUMOylated in vitro and in vivo
Analysis of human Polλ amino acid sequence by specialized software (SUMOplot, by Abgent; http://www.abgent.com/sumoplot) suggested that Polλ can be modified by SUMOylation. To confirm this prediction, we performed in vitro SUMOylation assays using purified proteins (Figure 1A and Supplemental Figure 1A ). In these assays we observed the appearance of low electrophoretic mobility species exclusively in the presence of ATP, an essential requirement for SUMO conjugation catalysis. A main modified protein showed an apparent increase in molecular weight of about 15-20 kDa with respect to unmodified protein when either SUMO1 or SUMO2 were included in the assays. This increase was in agreement with mono-SUMOylation of human Polλ (Figure 1A) . Moreover, other less represented species with slightly lower electrophoretic mobility were also observed with both SUMO paralogs, suggesting that different lysine residues could be additionally targeted with SUMO, although with less efficiency (Figure 1A) . We next analyzed whether Polλ SUMOylation also occurred in vivo by performing Ni-NTA pulldowns under denaturing conditions from human 293T cells co-expressing Flag-Polλ, His-SUMO1 and Ubc9, the only known E2 conjugation enzyme in mammalian cells. In these experimental conditions, SUMOylation of human Polλ was very efficient, and the size of the different low electrophoretic mobility species observed suggested the formation of poly-SUMO chains (Supplemental Figure 1B) . Of note, although a fraction of unmodified Polλ was pulled down from all samples, SUMO-Polλ species were stricly dependent on His-SUMO1 overexpression (Supplemental Figure 1B) . Notably, Polλ SUMOylation was detected at endogenous levels of Ubc9, and was strongly reduced in the presence of a dominant negative Ubc9 mutant that cannot catalyze SUMO conjugation to target proteins [27] (Supplemental Figure 1B) . SUMOylation of Polλ in vivo was also confirmed by using engineered human U2OS cell lines stably expressing His-tagged SUMO paralogs [28, 29] .
These cells were transiently transfected with the plasmid encoding for Flag-Polλ, and SUMO conjugates were pulled down from cell extracts as described above. In these experimental conditions, efficient SUMOylation of Polλ was also observed both with SUMO1 and SUMO2 paralogs, being the modification undetectable in control U2OS cells with untagged SUMO proteins ( Figure 1B) . Noteworthy, poly-SUMO chain formation in these experimental conditions was prevented by the molecular features of His-tagged SUMO paralogs expressed in these engineered cells [28, 29] . 5 Our initial analysis in silico predicted lysine 27 (K27) as the amino acid residue with the highest probability to be targeted by SUMO moiety in human Polλ (Supplemental Figure   2A and 2B). K27 is embedded in a highly conserved non-consensus SUMOylation motif located at the most N-terminal region of the protein (AKIP, with the underlined residue being the SUMO target; Supplemental Figure 2A ). This region is characterized by a great flexibility, that would be in agreement with previously reported SUMO preferential targeting to highly disordered regions [29] . We confirmed initial prediction by performing in vitro SUMOylation assays using peptide arrays that covered the most N-terminal region of human Polλ, including both K27 and all its proximal lysine residues (residues 8, 12, 15 and 23; Figure 1C and 1D). These assays showed the strongest SUMO targeting in peptides containing K27 (Figure 1D) , according to proteome-wide studies that had also identified this residue as the main target for Polλ SUMOylation (Supplemental Figure 2C ) [29] . We therefore generated the most conservative mutation of SUMO acceptor lysine (K27R mutation) and analyzed the effect on SUMOylation in vivo, as described above. In these assays, whereas a reduction of SUMO1 conjugation in K27R mutant compared to wildtype Polλ was barely detected, an evident decrease was observed in the case of SUMO2 conjugation (Figure 1E and 1F) . This effect could be explained to some extent by the lower efficiency of SUMO2 conjugation compared to SUMO1, already observed in vitro ( Figure 1B) . Likewise, these assays suggested the existence of alternative SUMOylation target sites in Polλ, also in agreement with results obtained in vitro ( Figure 1A) and with proteomic studies that identified K8 and K23 residues as alternative (secondary) lysines for SUMOylation in the N-terminal region (Supplemental Figure 2C ) [29] . To prevent SUMOylation of these alternative sites, we generated a mutant in which all seven Nterminal lysine residues, including K8, K12, K15, K23, K27 and two additional and more distant ones (K63 and K111) were equally substituted by arginines (mutant 7KR; Figure   1C ), and analyzed the effect of these mutations in SUMOylation of Polλ. This analysis showed a dramatic decrease of SUMO conjugation efficiency in 7KR mutant compared with wild-type Polλ, both with SUMO1 and SUMO2 (Figure 1E and 1F) . We obtained fully confirmation of Polλ K27 residue SUMO-specific targeting in vivo through generation of an additional mutant protein in which all N-terminal lysine residues except such K27 were mutated to arginine (mutant 6KR). Notably, this 6KR mutant fully recovered SUMOylation profile observed in vivo in wild-type Polλ, both with SUMO1 and SUMO2 (Figure 1E and   1F ). Altogether, these results indicate that K27 is actually the main target for SUMOylation in vivo. It is worth noting that because SUMOylation targets lysine residues of protein substrates, it can potentially compete with other lysine-directed PTMs like acetylation or 6 ubiquitylation [17] . Indeed, Polλ K27 has been identified as a target for ubiquitination, which controls Polλ levels during cell cycle [30] . In light of our results, it is tempting to speculate that K27 SUMOylation could antagonize the effects of ubiquitin, a competitive relationship that has been reported in many other proteins, including some DNA damage response factors [2, 17] .
Identification of Polλ SUMOylation sites
SUMOylation regulates subcellular localization of human Polλ
One of the first roles assigned to SUMOylation in vivo is to regulate subcellular localization of some target proteins, such as RanGAP protein, the first identified SUMO substrate [31] . Therefore, we analyzed by immunofluorescence the subcellular localization of Flag-tagged Polλ versions, including wild-type, mutants analyzed in previous in vivo assays (K27R, 7KR and 6KR) and two additional mutants affecting the nearest lysine amino acid residue K23 (K23R and K23/27R) (Figure 2A) . As expected from a DNA repair polymerase, the distribution of wild-type Polλ in human U2OS cells was predominantly nuclear (more than 92% cells). In contrast, Polλ K27R single mutant showed a markedly different subcellular distribution, with a fraction of the protein remaining outside the nucleus (more than 25%; p<0.01 in Anova test). This effect was specific of K27 amino acid residue, as it was not observed when mutation affected K23 residue (Figure 2A) . The abnormal distribution seen in K27R mutant was strongly exacerbated in Polλ 7KR, the mutant that was barely SUMOylated in vivo (Figure 1E and 1F) , which was almost completely excluded from the nucleus (Figure 2A) . Notably, this cytoplasmic distribution was abolished when the K27 residue became available again for SUMOylation, in the 6KR mutant, completely recovering the nuclear localization observed in the wild-type Polλ (Figure 2A) . These results suggest that SUMOylation at K27 residue controls Polλ entry into the nucleus in vivo. Alternatively, SUMO modification might be required to retain Polλ within the nucleus. Figure 4A ). We also replaced SUMO specific C-terminal double glycine residues by alanine residues in fusion proteins (S1-fusAA and S2-fusAA, respectively) to avoid SUMO removal due to the strong activity of SUMO-specific proteases (SENPs) in vivo [16] (Supplemental Figure 4A ). Genetic fusion of either SUMO1-AA or SUMO2-AA to Polλ 7KR mutant did not restore nuclear localization of Polλ (Supplemental Figure 4B ), suggesting that the presence of SUMO moiety in the N-terminus of Polλ, although necessary, is not enough to facilitate its entry into the nucleus. Nevertheless, given that both dynamism and reversibility are essential for cellular roles of SUMOylation, it is very likely that these fusion proteins might be incompatible with nucleo-cytoplasmic shuttling functions. A defect in the proper and functional folding of fusion proteins cannot be ruled out either. Regardless, our study uncovers the pivotal role of SUMOylation in the control of cellular distribution of Polλ, and identify the molecular basis of previous observations that Polλ catalytic core, a protein version lacking the amino terminal region including BRTC and Ser-Pro rich domains, is not able to enter into the nucleus [33, 34] .
Lack of SUMOylation results in decreased Polλ recruitment to etoposide-induced
DSBs
Given its relevance in the nuclear localization of Polλ, we wanted to determine the consequences of interfering with SUMOylation on its recruitment to DNA lesions. Among other functions, Polλ is involved in the repair of a subset of DNA DSBs through NHEJ [8, 9, 15] . To specifically measure Polλ recruitment to DSBs, we developed an experimental approach based on proximity ligation assays (PLA) that uses specific antibodies for human Polλ and phosphorylated histone H2AX (γH2AX), a well known marker of DSBs in mammalian cells [35, 36] . We validated the use of this molecular tool to measure the recruitment of Polλ to specific nuclear DSBs in vivo by analyzing the formation of PLA foci of endogenous γH2AX and Polλ in human U2OS cells treated with the DSB-inducing drug etoposide. In these experimental conditions, we observed an increase in the number of PLA foci that was directly proportional to the dose of etoposide used (Supplemental DSBs, independently of the SUMO-mediated pathway, cannot be excluded. Accordingly, novel interactions between Polλ NLS derived peptides and cellular importins have been recently described [37] . Future studies, both structural and functional, will clarify these alternative pathways and putative synergies with the findings uncovered in our study.
RanBP2 E3 ligase mediates Polλ SUMOylation and nuclear localization
SUMOylation of natural substrates in vivo is facilitated by a variety of E3 protein ligases, specially in proteins, as Polλ, lacking consensus SUMO acceptor motifs [16, 25] . To date, the only non-nuclear E3 ligase identified is nuclear pore complex-associated RanBP2 protein, that can form a stable complex with both SUMO1 and Ubc9 throughout the cell cycle and promote the last step in the SUMOylation process [38] [39] [40] . Considering this, and the nucleo-cytoplasmic shuttling defect seen in our Polλ mutants (Figure 2A Figure 6 ). Moreover, we detected direct interaction of these two proteins by co-immunoprecipitation in the absence of any external stimulus (Figure 3B ), suggesting that Polλ might be targeted for RanBP2-mediated SUMOylation constitutively.
To verify a functional interaction between RanBP2 E3 ligase and Polλ, we performed His-SUMO pulldown assays as those described above in U2OS cells that were previously treated with RanBP2 specific siRNAs. In these experimental conditions, we observed that the reduction in RanBP2 expression led to a strong concomitant decrease in conjugation of SUMO to Polλ (Figure 3C and 3D) . This effect was not seen in cells treated with control non-targeting siRNAs, so that confirmed RanBP2 as the main E3 ligase involved in Polλ SUMOylation. In the same way, immunofluorescence assays performed in Flag-Polλ expressing U2OS cells that had been silenced for RanBP2 expression also showed a 9 strong decrease of Flag-Polλ nuclear localization when compared to cells treated with control non-targeting siRNAs (Figure 3E ; more that 40% reduction in nuclear localization; p<0.001 in an unpaired t-test). These results were in fully agreement with those obtained with non-SUMOylatable Polλ mutants in our in vivo SUMOylation assays (Figure 2A) .
Altogether, our results indicate that RanBP2 is the main E3 ligase participating in SUMOmediated modification of human Polλ to promote its nuclear import. Of note, nuclear import of artificial cargos can still occur in vivo in RanBP2-depleted cells, although rates are substantially reduced [26] . This could explain residual nuclear Polλ observed in our analyses with K27R single mutant (Figure 2A) , and, again, suggest the existence of SUMO-independent pathways, still to be deciphered, through which Polλ could enter into the nucleus.
Polλ SUMOylation is enhanced after MMS-mediated DNA damage induction
Once demonstrated the involvement of RanBP2-dependent SUMOylation at the nuclear pore complex in the translocation of Polλ into the nucleoplasm, we wanted to determine if this molecular mechanism was affected by DNA damage. By using engineered human U2OS cell lines stably expressing His-tagged SUMO paralogs described above, we were able to efficiently detect SUMOylation of endogenous Polλ in Ni-NTA pull down assays ( Figure 4A) . This allowed us to evaluate the effect of DNA damage induction on Polλ SUMOylation in more physiological conditions. Such analysis revealed an increase of Polλ SUMOylation when cells were subjected to DNA damage induction, being the increase specially evident in response to the DNA alkylating agent methyl methanesulfonate (MMS) (Figure 4B and 4C) . MMS-induced DNA lesions are mainly repaired by base excision repair (BER), a repair pathway in which DNA polymerase ß is the main gap-filling DNA polymerase [41, 42] . Although Polλ participation in this repair route was initially suggested as a back-up mechanism in mouse cells [43] , it has also been shown that cells deficient in both Polλ and Polß are hypersensitive to MMS [5] , suggesting that both PolX enzymes synergistically participate in the repair of a common set of DNA lesions. Interestingly, it has been recently reported that human Polλ can also perfectly complement the absence of Polß in POLB-deficient cell extracts, leading authors to suggest that Polλ might be sequestered in vivo in a complex with other proteins or post-translationally modified in a way that limits its ability to participate effectively in BER in normal conditions [44] . Overall, our results would be in agreement with a model in which, if Polß is overcome by the amount of damage generated by MMS, a greater requirement of nuclear Polλ would be needed, that might be achieved through the SUMO-mediated translocation of Polλ into the nucleus. It is worth noting that main SUMOylation site in Polλ (K27 residue) is, in turn, target site for ubiquitination, which is a signal for its subsequently degradation via proteasome [30] . Therefore, it cannot be ruled out that SUMOylation at K27 makes Polλ more stable and, therefore, more active in the repair of MMS-induced damage. Future studies will be necessary to validate this model and elucidate the precise role of Polλ SUMOylation in BER regulation. On the other hand, it is equally noteworthy that MMS produces a wide variety of DNA lesions, some of which prevent the progression of replication forks [45] . Therefore, one possibility would be that the increase in Polλ SUMOylation in response to MMS is related to replication forks problems. In agreement with this, replicative stress induced with hydroxyurea (HU) also caused a concomitant increase in SUMOylation of Polλ (Figure 4C and Supplemental Figure 7) . In spite of this, we did not detect significant differences in Polλ SUMOylation at different stages of a cell cycle in human U2OS cells (Figure 4D) . Overall, our data suggest that SUMOylation is a relevant signal for human Polλ to entry the nucleus in situations where its gap-filling activity can be specially required, e.g., during MMS-triggered BER or upon replicative stress.
Concluding Remarks
Detailed knowledge of the post-translational regulation of DNA repair proteins is essential to understand how cells deploy the complicated and tangled network of processes that constitute the DNA damage response. Finely coordinated functioning of this complex network will determine cell viability and prevent the development of age-related diseases and cancer. In particular, it is of great interest to decipher the molecular mechanisms that allow DNA repair factors to enter the nucleus and accomplish their functions, which can have negative consequences for the cell, for example contributing to tumorigenesis as a consequence of inefficient DNA repair [45] . In this work we have identified SUMOylation as a novel post-translational modification of human DNA repair polymerase lambda (Polλ) with a relevant influence in its potential functionality in vivo. We have uncovered that SUMO modification fundamentally occurs at N-terminal K27 amino acid residue and requires E3 activity ligase from RanBP2, a nucleoporin present in the outer side of the nuclear envelope. Likewise, we have discovered that nuclear localization of human Polλ is SUMO-dependent, so that such modification is required for Polλ to be recruited to DNA lesions to perform its function. It is worth noting that transport pathways may offer attractive therapeutic targets, as they represent a very selective way of cancelling a biological activity without affecting others. Consequently, the nature of the molecular pathway described here suggests that preventing Polλ SUMOylation by using small molecule inhibitors of this specific modification (for example, blocking SUMO-acceptor sites) could be a suitable point to abolish its polymerase activity in the nucleus, which could be interesting in order to explore the effect of selective Polλ inhibition on tumor cell growth. High levels of replicative stress and excess of oxidative lesions (i.e. ROS) are a hallmark of tumor cells that will demand a great functioning of BER and DNA damage tolerance pathways. Disrupting the cellular mechanisms that cope with this aberrant situation, for example by inhibiting the ATR or Chk1 kinases, constitutes a very promising strategy for cancer treatment [47, 48] . Interestingly, the suppression of Polλ activity induces synthetic lethality when combined with Chk1 inhibitors [49] , what turns Polλ and its nucleocytoplasmic shuttling as additional potential chemotherapeutic target to be analyzed in more detail. Importantly, targeting the N-terminal region of Polλ would solve undesired effects of many of Polλ inhibitors identified so far, that can also affect other polymerases, in particular those from PolX family, due to high similarity in their catalytic center [50, 51] .
Although further structural studies should be needed to gain molecular insights of Polλ Nterminal region, some pioneering work performed with the murine ortholog already shed some light in this regard [33] . Finally, another attractive scenario to be explored regarding Polλ SUMOylation inhibition would be related with CRISPR-Cas based gene editing tools.
These systems strongly rely on the processing of directed DSBs by the cellular NHEJ repair machinery. The possibility of controlling CRISPR-based gene editing accuracy by pharmacological modulation of the repair process is being intensively evaluated at present [52] . In this regard, the search for selective inhibitors against Polλ SUMOylation could also be useful in the gene editing toolkit, given that a large subset of breaks generated by CRISPR-Cas systems requires specialized DNA gap-filling activity by PolX polymerases as Polλ [53, 54] .
MATERIALS AND METHODS
Cell cultures
Human embryonic kidney 293T cells and human osteosarcoma cells (U2OS, U2OS HIS-SUMO1 and -SUMO2 expressing cells) [28, 29] were cultured in DMEM medium (Sigma) supplemented with 10% fetal bovine serum (Sigma), 2 mM L-glutamine and antibiotics (100 units/ml penicillin, 100 µg/ml streptomycin; Sigma) at 37°C in a humidified atmosphere containing 5% CO2. Transient transfections of plasmids were performed with Lipofectamine (Life Technologies) according to manufacturer's instructions.
Plasmid constructs and siRNA
Wild-type POLL cDNA was amplified by PCR and cloned in the p3xFlag-Myc-CMV expression vector (Sigma) as previously described [15] . POLL mutants were generated by site directed mutagenesis using p3xFlag-[POLL]-Myc-CMV and overlap extension PCR methodology with oligonucleotides listed in Table S1 . POLL K6R mutant was generated by site directed mutagenesis that reverted K27R mutation from p3xFlag-[POLL 7KR]-Myc-CMV plasmid, and both Polλ and Polλ7KR siRNA resistant clones were generated by using the oligonucleotides indicated in Table S1 using the p3xFlag-[POLL]-Myc-CMV and p3xFlag-[POLL 7KR]-Myc-CMV plasmids, respectively. All mutated cDNAs were verified by DNA sequencing. Constitutive SUMO-Polλ versions (both with SUMO1 and SUMO2) were generated by PCR amplification of either SUMO1 or SUMO2 cDNA by using oligonucleotide primers with flanking BglII cut sites (see Table S1 ). PCR products were digested with BglII, cloned into p3xFlag-[POLL]-Myc-CMV expression vector and sequenced to verify proper orientation of fusion cDNAs. Site directed mutagenesis of the C-terminal di-glycine motif of SUMO proteins was performed on these plasmids by using oligonucleotides listed in Table S1 and overlap extension PCR methodology. Efficient silencing of endogenous POLL and RANBP2 genes was achieved by two consecutive rounds of transfection of previously validated double-stranded siRNAs (Table S1) wild-type Flag-POLL was previously described [15] , and siRNA resistant clones of Flag-13 POLL 7KR were obtained by using oligonucleotides listed in Table S1 and Q5 Site Directed Mutagenesis kit (NEB) following manufacturer's instructions. 
Proteins and in vitro
In vitro SUMOylation on peptide arrays
For in vitro SUMOylation assays on peptide-scanning arrays, N-terminal acetylated overlapping dodecapeptides covering the N-terminal region of human Polλ were generated by automated spot synthesis onto an amino-derivatized cellulose membrane (CNB Proteomics Core Facility, Proteored, Spain). Peptides were immobilized by their C-termini via a polyethylene glycol spacer. Overlapping peptides were spotted onto membrane so that they shared 10 amino acids with its adjacent peptide on the array, corresponding to a change of two amino acids per peptide. Peptide array membrane was blocked overnight in 1% BSA and 3% Tween-20 before SUMO-conjugation on cellulose-bound peptides. Briefly, enzymatic reaction was performed in a reaction mixture containing 5mM ATP, 50mM NaCl, 5mM MgCl2, 0.2M DTT, 1% BSA and 3% Tween-20, and 0.15 µM E1, 0.20 µM E2 and 0.4 µM SUMO1 proteins for 30 min at 37ºC. Nonspecifically bound proteins were washed off by sonication for 2 min in a bath containing 1% SDS, 0.1% ß-mercaptoethanol and 100mM
Na2HPO4. Further nonspecific binding was blocked by incubation with 3% BSA-1% Tween-20 in TBS for 1 hour. Subsequently, the membrane was incubated for 2 hours with anti-SUMO1 primary antibody diluted in blocking solution (1:1,000 dilution). Membranes 14 were washed with TBS-Tween-20 (0.1%) and subsequently incubated with HRPconjugated secondary antibody diluted in blocking solution for 1 hour. Membranes were washed extensively with TBS-T (0.1%) and SUMO1 signal was detected by ECL incubation following the manufacturer's instructions. 
Immunoblotting, immunoprecipitation and pulldown assays
Immunofluorescence
For standard immunofluorescence studies approximately 2×10 4 U2OS cells were seeded onto sterile glass coverslips in each well of a four-well dish, cultured for 24 hours and transfected with Flag-POLL constructs as described above. For immunofluorescence studies involving siRNA-mediated silencing of endogenous Polλ or RanBP2, 2.5×10 4 , U2OS cells were seeded onto sterile glass coverslips in each well of a four-well dish and cultured for 24 hours. Silencing of endogenous POLL or RANBP2 was performed as described above. After 72 h, cells were fixed by treatment with 4% formaldehyde in PBS at room temperature for 10 min, and then permeabilized by treatment with 0.2% Triton X-100 in PBS. Cells were incubated with PBS-1% BSA for 30 min to block non-specific antigens, and then were incubated with mouse monoclonal anti-Flag M2 (Sigma; 1/5,000) diluted in PBS-1% BSA. After washes with PBS-0.1% Tween20, cells were incubated with Alexa 594
Fluor-conjugated secondary antibodies (Jackson; 1/1,000) and washed again as described above. Finally, they were counterstained with 4,6 diamidino-2-phenylindole (DAPI 1 µg/ml; Sigma) and mounted using Vectashield mounting medium (Vector Laboratories). Samples 16 were visualized and pictures taken by using a Leyca DM6000B fluorescence microscope with a HCX PL APO 63x/NA 1.40 oil immersion objective. For proximity ligation assays (PLA) human U2OS cells were grown on sterile glass coverslips and co-transfected with both HA-RanBP2 and Flag-Polλ as described before. For PLA assays to analyze and measure endogenous Polλ and γH2AX proximity, transfection step was omitted. After 48 hours, cells were fixed and permeabilized as described above. PLA assays were performed using the Duolink PLA kit (Sigma) according to manufacturer's instructions with following antibodies: rabbit anti-Polλ (A301-640A Bethyl; 1/1,000), mouse monoclonal anti-RanBP2 antibody (sc-74518, Santa Cruz; 1/1,000) and mouse monoclonal anti-γH2AX (clone JBW301, Millipore; 1/1,000). For PLA assays measuring transfected Flag-Polλ (either si-RNA resistant WT or 7KR mutant) and γH2AX proximity, positively transfected cells were identified by performing post-PLA staining by using Alexa A488 fluor-conjugated anti-rabbit secondary antibodies (Jackson; 1/1,000). After final wash step, cells were counterstained with DAPI and mounted as described above. Confocal analysis was performed with a Leica confocal microscope TCS SP5, using a HCX PL APO lambda blue 63x 1.4 objective with zoom 3. Image stacks were captured keeping a step size of 0.5 microns and sequential scanning was defined for each channel using 543 nm, 488 nm and 405 nm laser lines, respectively. 
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